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2Abstract 
The quality control system of the endoplasmic reticulum (ER) discriminates between 
native and non-native proteins. The latter are degraded by the ER-associated 
degradation (ERAD) pathway. While many cytosolic and membrane components of 
this system are known, only few luminal players have been identified. In this study, 
we characterize ERFAD (ER Flavoprotein Associated with Degradation), a novel ER 
luminal flavoprotein that functions in ERAD. Upon knockdown of ERFAD, the 
degradation of the ERAD model substrate ribophorin 332 is delayed, and the overall 
level of polyubiquitinated cellular proteins is decreased. We also identify the ERAD 
components SEL1L, OS-9 and ERdj5, a known reductase of ERAD substrates, as 
interaction partners of ERFAD. Our data show that ERFAD facilitates the dislocation 
of certain ERAD substrates to the cytosol, and we discuss the findings in relation to a 
potential redox function of the protein. 
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Introduction 
In the secretory pathway, critical protein maturation steps occur in the endoplasmic 
reticulum (ER). During translocation of the polypeptide chain into the ER, 
modifications such as N-glycosylation and disulfide-bond formation take place and a 
variety of chaperones assist folding. While native proteins can exit the ER by the 
secretory pathway, misfolded proteins and incompletely assembled protein complexes 
are retained by the quality control machinery of the ER (1). To prevent their toxic 
accumulation, non-native proteins are degraded by the cytosolic ubiquitin-proteasome 
system. First, proteins must be recognized as non-native. They are then transported to 
the site of retrotranslocation and extracted from the ER. Partial unfolding and/or 
reduction are likely prerequisites for transport across the membrane for many 
proteins. In the cytosol, proteins become polyubiquitinated by ubiquitin ligases before 
degradation by the proteasome. Collectively, the various steps of this process are 
known as ER-associated degradation (ERAD) (2, 3).  
 
Different ERAD pathways have been defined (3). One of them is the Hrd-ligase 
pathway. In yeast and presumably in metazoans it mediates the degradation of 
proteins with luminal lesions (4). The central components of this pathway are two 
closely associated membrane proteins, the ubiquitin ligase Hrd1 (Hrd1p in yeast) and 
SEL1L (Hrd3p). SEL1L contains a large luminal domain (5-7) that likely serves as an 
adaptor platform for ERAD factors such as the chaperones BiP (Kar2p) and GRP94 as 
well as the lectin OS-9 (Yos9p) (5, 6, 8). These factors deliver misfolded proteins to 
SEL1L and thereby mediate the recognition of luminal substrates by the Hrd-ligase 
complex (9-12). 
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After the initial recognition step, disulfide bonds in ERAD substrates can be reduced 
by ERdj5 (13), a thiol-disulfide oxidoreductase of the protein disulfide isomerase 
(PDI) family, and luminal ERAD substrates traverse the ER membrane likely through 
a retrotranslocation channel (2). In the cytosol, all known ERAD pathways converge 
at the AAA-ATPase p97 that extracts substrates from the ER (14, 15). If substrates 
contain N-glycans, they are deglycosylated at this stage by the cytosolic peptidyl:N-
glycanase (Png1) (16) before being degraded by the proteasome (17).  
 
Here, we identify the previously uncharacterized ER luminal flavoprotein ERFAD 
that we show to interact with SEL1L, OS-9 and ERdj5. Moreover, downregulation of 
ERFAD stabilizes the ERAD substrate RI332 and reduces the cellular level of 
polyubiquitinated proteins. Based on the data, and in light of the unique sequence 
features of ERFAD, we discuss possible mechanisms of action in ERAD.  
 
Results and Discussion 
ERFAD is a novel flavoprotein of the ER 
To find novel redox-active ER proteins we performed database searching for 
homologs of the cytosolic protein glutathione reductase (GR). This enzyme utilizes 
the two redox cofactors NADPH and FAD. During catalysis, two NADPH-derived 
electrons are transferred via FAD onto a pair of cysteines that then acts as a disulfide 
reductant. Performing a BLAST search with GR as query sequence we identified a 
previously uncharacterized open reading frame (RefSeq: NP_079231, gene name: 
FOXRED2) that encodes a protein of 684 amino acids. Unlike GR, the N-terminal 26 
residues are predicted to constitute an ER signal peptide and the protein contains a C-
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terminal ‘KEEL’ ER-retrieval motif characteristic of soluble ER proteins (Fig. 1A). 
Based on this in silico analysis and on our functional studies (see below), we termed 
the protein ER Flavoprotein Associated with Degradation (ERFAD). Whereas the C-
terminal ~250 residues of ERFAD do not contain any known domains, the N-terminal 
~400 residues of the protein comprise, like GR and the related thioredoxin reductase 
(TR), consensus motifs for the binding of the two redox cofactors FAD and NADPH 
(Fig. 1A). It is noteworthy that despite the homology to GR and TR, ERFAD does not 
contain an equivalent of the redox-active Cys-Xaa4-Cys motif found in these two 
enzymes, making it unlikely that ERFAD functions by the same mechanism. Database 
searching revealed orthologs of ERFAD in a number of vertebrates, urochordates and 
in S. purpuratus (a sea urchin) and O. tauri (an algae), but not in the model organisms 
S. cerevisiae, D. melanogaster and C. elegans. In silico and RT-PCR analysis showed 
a broad tissue distribution of human ERFAD transcripts (Fig. 1B). 
 
To investigate whether ERFAD is indeed a flavoprotein, we purified ERFAD from a 
HEK293 cell line stably expressing the full-length protein containing C-terminal 
hexa-His and FLAG tags (3B2B cells) (Fig. 1C). While in most preparations we 
detected only pure ERFAD, in others we co-purified varying amounts of BiP. This 
suggested that a fraction of ERFAD-His-FLAG, which was heavily overexpressed in 
3B2B cells (~ 30 times compared to endogenous levels, data not shown), required BiP 
binding to remain soluble. In the absorption spectrum of purified ERFAD we detected 
two peaks with maxima at 370 and 450 nm characteristic of a flavin cofactor in 
addition to the protein peak at 280 nm (Fig. 1D). To assess the cofactor binding in 
more detail we released the flavin with 0.1% SDS and separated it from the protein by 
filtration. In the filtrate we observed a fluorescence emission peak at 535 nm upon 
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excitation at 450 nm (data not shown). Typical for free FAD (and not FMN) (18), this 
signal increased upon acidification of the solution to pH 3. Such a signal was not 
observed without prior denaturation of the protein indicating the specific binding of 
FAD to ERFAD (data not shown).  
 
To facilitate the analysis of endogenous ERFAD, we raised an antiserum against the 
denatured full-length protein. After affinity purification this antiserum recognized a 
band of ∼80 kDa corresponding to ERFAD (calculated molecular mass of 75.3 kDa 
without N-glycans) and a second weaker band at ∼75 kDa (Fig. 1, E and F; Fig. S1A). 
The latter band likely represents a protein unrelated to ERFAD since siRNA-mediated 
downregulation of ERFAD reduced the intensity of the 80 kDa band only (Fig. S3A 
and S3C). As expected for an ER protein with five potential N-glycosylation sites 
(Fig. 1A), increased mobility was observed upon EndoH cleavage (Fig. 1E). Non-
reducing SDS-PAGE resulted in only a marginal shift of the ERFAD band, suggesting 
that none of the six cysteines in ERFAD (Fig. 1A) are enganged in long-range 
intramolecular disulfide bonds (Fig. 1E). Alkali extraction of crude membranes 
demonstrated that ERFAD is a soluble protein (Fig. 1F). In immunofluorescence 
microscopy we observed a reticular staining pattern for ERFAD and co-localization 
with the ER chaperone Hsp47 (Fig. 1G). A similar result was obtained with 
transiently expressed HA-tagged ERFAD (Fig. S1B). We concluded that ERFAD is a 
ubiquitous soluble N-glycosylated ER flavoprotein.  
 
ERFAD interacts with the ERAD components SEL1L, OS-9 and ERdj5 
To provide clues for the cellular function of ERFAD we set out to identify interaction 
partners. For this purpose, we generated a HEK293-derived cell line stably expressing 
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the protein with an HA tag inserted immediately prior to the C-terminal KEEL 
sequence (A11 cells). Immunoprecipitation of ERFAD-HA with two different 
monoclonal HA antibodies (16B12 and 12CA5) revealed one clear candidate 
interacting protein (Fig. 2A, arrowheads). This protein had an apparent size of ∼90 
kDa and contained EndoH-sensitive glycans (Fig. 2B). The interaction was not 
dependent on the formation of intermolecular disulfide bonds (data not shown). 
Scaling up of the co-immunoprecipitation experiment allowed protein identification 
by mass spectrometry on a glycosidase-treated sample. The results showed the 
excised band to contain the important ERAD component SEL1L. 
 
To verify the interaction between ERFAD and SEL1L we immunoprecipitated 
ERFAD-HA from A11 cells and analyzed the eluate by Western blotting using anti-
SEL1L (Fig. 2C, lane 4). In another experiment, we immunoprecipitated SEL1L from 
A11 cells and blotted the eluted proteins with anti-HA (Fig. 2D, lane 4). In both cases, 
we observed an interaction between the two proteins (Fig. 2C and D, lane 2). We 
could also detect the interaction between endogenous ERFAD and SEL1L when using 
the thiol-cleavable crosslinker dithiobis(succinimidyl)propionate (DSP) to stabilize 
the complex (Fig. 2E, lane 3). In addition to SEL1L, we found ERFAD to interact 
with two further ERAD proteins. First, the immunoprecipitate of ERFAD-HA from 
A11 cells contained both isoforms of OS-9 (Fig. 2F). Secondly, the PDI-family 
member ERdj5 precipitated with endogenous ERFAD (Fig. 2G, lane 2; Fig. 2H, lane 
1), and ERFAD precipitated with endogenous ERdj5 (Fig. 2G, lane 6). 
 
Interestingly, when using DSP we precipitated with ERFAD several additional 
proteins that were also recovered when reprecipitating SEL1L (Fig. 2E, lanes 3 and 
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4). When analyzing the precipitate under non-reducing conditions that leave 
crosslinks intact, we found that it appeared as a high molecular weight smear 
suggesting that ERFAD functions in a larger complex (Fig. 2I, lane 8). The identity of 
the interacting proteins is currently unknown.  
 
ERFAD knockdown inhibits the degradation of RI332  
The identification of the three known ERAD components SEL1L, OS-9 and ERdj5 as 
interaction partners suggested a role of ERFAD in ERAD. For investigations of a 
potential ERAD function we established siRNA-mediated downregulation of ERFAD 
(Fig. S3). Although a slight increase in PERK phosphorylation was observed, ERFAD 
downregulation did not considerably induce the unfolded protein response (Fig. S4, 
A-C). Furthermore, it neither influenced significantly the steady-state levels and redox 
states of selected ER oxidoreductases (PDI, ERp57, TMX3) or the steady-state level 
of p97 (Fig. S4D-F), nor did it perturb the oxidative refolding of the disulfide-
containing immunoglobulin J-chain after DTT washout (Fig. S4H). We also 
investigated the in vivo redox state of ERdj5, and showed it to be almost completely 
oxidized at steady state (Fig. S4G). Unfortunately, the assay did not provide a definite 
conclusion as to whether the redox state of a single among the four redox-active 
cysteine pairs in ERdj5 was affected by ERFAD knockdown of (see Supplemental 
Information for a discussion). Overall, ERFAD downregulation did not seem to 
influence general ER homeostasis and redox conditions. 
 
We next investigated effects of ERFAD downregulation on model protein 
degradation. Ribophorin 332 (RI332), a truncated soluble variant of the oligosaccharyl 
transferase-component ribophorin I (19), is degraded in a SEL1L-dependent manner 
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(5). We therefore tested by pulse-chase analysis the effect of ERFAD knockdown on 
the stability of RI332 in a HEK293 cell line that stably expresses RI332 (HEK293-
RI332). Immunoprecipitation with anti-ribophorin retrieved both RI332 and wild-type 
ribophorin I. Because the latter remained unaffected by ERFAD knockdown and is a 
stable protein with a half-life of 25 hours (20), it was used to normalize the RI332 
signal. We observed a significant stabilization of RI332 upon ERFAD downregulation 
(Fig. 3A and B). In contrast, the degradation kinetics of the α-subunit of the T-cell 
receptor complex (TCRα) was not significantly affected by ERFAD knockdown (Fig. 
S5, A and B), a result that fits well with the observation that TCRα is only marginally 
(if at all) influenced by SEL1L downregulation (5, 21). A similar result was observed 
for another ERAD substrate, the nonsecreted immunoglobulin κ light chain (NS1κLC; 
(22)) (Fig. S5, C and D). In the same fashion, downregulation of other ERAD 
components such as OS-9 and XTP3-B only affected the degradation of certain 
specific substrates but not of others (8, 23, 24).  
 
ERFAD knockdown leads to the accumulation of the glycosylated ER form of 
RI332  
Having established a stabilizing influence of ERFAD downregulation on RI332, we 
next investigated the possibility that this effect was due to an accumulation of RI332 in 
the ER lumen. While luminal RI332 carries an N-glycan, the cytosolic 
(retrotranslocated) form becomes deglycosylated by Png1 before degradation by the 
proteasome (19, 25). This property allows assignment of RI332 to the ER or the 
cytosol. We immunoprecipitated RI332 from HEK293-RI332 cells that had been pulse-
labeled and chased in the presence of the proteasome inhibitor MG132. The result 
showed that significantly more glycosylated RI332 remained upon ERFAD knockdown 
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compared to control conditions (Fig. 3, C and D). To exclude that MG132 treatment 
prevented a fraction of RI332 from entering the ER and becoming glycosylated, we 
analyzed HEK293-RI332 cells directly after the pulse. Under these conditions, and 
irrespective of ERFAD knockdown, almost all RI332 was present in the glycosylated 
ER form (data not shown), showing that in the above experiment, deglycosylated 
RI332 indeed constituted the retrotranslocated fraction. In summary, our data strongly 
suggested that RI332 is retained in the ER lumen when ERFAD levels are lowered. 
 
ERFAD interacts with RI332 
The results so far indicated that ERFAD, like SEL1L, plays a role in the degradation 
of RI332. We therefore evaluated whether ERFAD and RI332 could be precipitated in 
the same complex. To this end, we immunoprecipitated ERFAD from extracts of 
MG132-treated [35S]-methionine-labeled HEK293-RI332 cells. Indeed, when re-
immunoprecipitating RI332 we predominantly recovered the glycosylated form of the 
protein (Fig. 3E and S6A, lanes 3 and 3’; the identity of the different RI332 forms is 
discussed in the Fig. S6A figure legend). In an equivalent experiment using anti-
SEL1L for re-immunoprecipitation, we could show that SEL1L, exactly like ERFAD, 
mainly co-precipitated glycosylated RI332 (Fig. S6B). The finding that ERFAD 
coprecipitates RI332 – and not full-length ribophorin (Fig. 3E and data not shown) – 
further supports the direct involvement of ERFAD in the degradation of this ERAD 
substrate. 
 
The level of polyubiquitinated proteins is decreased upon ERFAD knockdown 
To evaluate the overall role of ERFAD in dislocation of ER proteins targeted for 
ERAD, we investigated the influence of ERFAD knockdown on the total cellular pool 
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of polyubiquitinated proteins. A fraction of these polyubiquitinated proteins are 
ERAD substrates that are polyubiquitinated in the cytosol directly after or during 
extraction from the ER (26). As a positive control we treated cells with MG132, 
which led to the accumulation of polyubiquitinated proteins (Fig. 4A). In contrast, 
ERFAD knockdown resulted in a clear reduction in the level of polyubiquitinated 
proteins (Fig. 4, B and C). The decreased levels of polyubiquitination induced by 
ERFAD deprivation – very much like the changes in polyubiquitination observed 
upon knockdown of the ER oxidoreductases PDI and ERp72 (27, 28) – were not 
accompanied by an induction of the unfolded protein response (Fig. S4). 
 
Conclusions 
Our detailed analysis of ERAD model substrate degradation functionally connects the 
novel ER-luminal protein ERFAD to ERAD. Moreover, complex formation of 
ERFAD with SEL1L, OS-9 and ERdj5, and the observed effect of ERFAD 
knockdown on polyubiquitination provided additional links between ERFAD and the 
process of ERAD. Since the results were obtained by a variety of experimental 
techniques (including co-precipitation of endogenous proteins), they are unlikely to 
reflect indirect effects of ERFAD inactivation or overexpression. Notably, ERFAD 
downregulation did not prevent oxidative folding or change general ER redox 
conditions, and only marginally induced the unfolded protein response. Overall, our 
results present a coherent set of data that demonstrates a direct role of ERFAD in 
ERAD. 
 
We show that the interaction with ERFAD is required for efficient retrotranslocation 
and degradation of RI332, an established substrate of the SEL1L/Hrd1 ERAD pathway 
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(5). Conversely, we observed no effect of ERFAD knockdown on the degradation of 
the Hrd1-independent ERAD substrate TCRα or on NS1κLC (Fig. S5), a disulfide-
containing ERAD substrate that becomes reduced by an unknown process before 
retrotranslocation (22). Given the putative redox activity of ERFAD (see below), the 
identification of RI332, which lacks disulfides, as a substrate for ERFAD may appear 
unexpected. However, ERFAD need not be restricted to promoting degradation of 
disulfide-containing ERAD substrates, as illustrated by the finding that the ER 
oxidoreductase PDI assists the retrotranslocation of Dgpaf, which does not contain 
disulfides (29).  
 
Our studies show that ERFAD is a flavoprotein. Despite considerable effort, we were 
unable to purify sufficient amounts of the protein to reliably determine if it is capable 
of utilizing NADPH. However, the in silico analysis strongly suggests that ERFAD 
uses both FAD and NADPH, a unique feature among known ER proteins. Moreover, 
we show ERFAD to interact with ERdj5 that reduces disulfides in ERAD substrates 
(13). With FAD and NADPH as redox cofactors, ERFAD should be able to provide 
the electrons for the reduction of the active-site cysteines in ERdj5. While we do not 
have direct evidence that ERFAD is a reductase for ERdj5, this will be an obvious 
working hypothesis to guide future experiments. Further cell biological and 
biochemical studies will be aimed at improving mechanistic insight into the function 
of ERFAD. 
 
Materials and Methods 
Primers and plasmids 
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The ERFAD cDNA clone IMAGE3873448 (9629-g17) was acquired from the 
I.M.A.G.E. consortium. The plasmids pcDNA3, pcDNA5-FRT and pOG44 were 
obtained from Invitrogen. The RI332 construct was a gift from N. E. Ivessa, University 
of Vienna and the NS1 κ LC construct was a gift from L. Hendershot, St. Jude 
Children's Research Hospital. The following plasmids were constructed as described 
in the Supplemental Materials and Methods: pcDNA3/ERFAD-HA, pcDNA5-
FRT/ERFAD-HA, pRSETminiT/His-ERFAD and pcDNA3/HA-NS1 κLC.  
 
Antibodies 
Antibodies against the following proteins and peptide tags were used: actin (Sigma), 
BiP (Santa Cruz Biotechnology), eIF2α and eIF2α-phosphate (Cellular Signalling), 
ERdj5 (Abcam), ERp57 (gift from A. Helenius, ETH Zurich), anti-GFP (Invitrogen), 
HA (12CA5, gift from M. Peter, ETH Zurich and 16B12, Covance), tetra-His 
(Qiagen), Hsp47 (Stressgen), myc (9E10, Covance), OS-9 (Novus), p97 (30) and 
p112 (Biomol), PDI (Stressgen), ribophorin (gift from N. E. Ivessa, University of 
Vienna), SEL1L (gift from H. Ploegh, Whitehead Institute, Cambridge, MA), TMX3 
(31) and ubiquitin (Dako). The secondary anti-rabbit and anti-mouse IgG coupled to 
horseradish peroxidase were obtained from Pierce and the Alexa Fluor 594 anti-
mouse IgG from Invitrogen. A polyclonal serum against ERFAD was generated by 
immunizing rabbits with the full length denatured His-ERFAD protein expressed in 
E.coli. The obtained 1F6 antiserum was affinity purified (32) and used for Western 
blotting. For immunoprecipitations, the polyclonal anti-peptide serum SG2480 
generated by immunizing rabbits with the C-terminal peptide of ERFAD 
(CGPLAQSVDSNKEEL) was used.  
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Cell lines 
HEK293-TCRα-GFP cells were a gift of R. Kopito, Stanford University. Stable cell 
lines were either generated using the Flp-In system from Invitrogen (A11, ERFAD-
HA in HEK293-FRT, selected with 0.1 mg/ml hygromycin B) or by calcium 
phosphate transfection of HEK293 cells with pcDNA3/ERFAD-His-FLAG (3B2B), 
pcDNA3/RI332 (HEK293-RI332), pcDNA3/myc-J-chain (HEK293-myc-J-chain) or 
pcDNA3/HA-NSκLC (HEK293-HA-NSκLC) and subsequent selection with 1 mg/ml 
geneticin. All cells were cultured in modified Eagle medium alpha (Gibco) 
supplemented with 10% fetal calf serum (LabForce AG). Stable cells were 
additionally supplemented with the respective antibiotic. 
 
ERFAD-His-FLAG expression and purification 
ERFAD-His-FLAG was purified from 3B2B cells adapted to suspension growth in 
spinner flasks. Cells were grown to a density of 1.5x 106 cells/ml and harvested by 
centrifugation. The pellet was washed with PBS and resuspended in lysis buffer (TBS 
(50 mM Tris/HCl pH 7.5, 150 mM NaCl) containing 1 % Triton X-100). The cleared 
lysate was applied onto an M2-FLAG affinity matrix (Sigma). The matrix was washed 
with 100 bed volumes of lysis buffer followed by TBS and eluted with 0.1 mg/ml 
FLAG peptide in TBS. ERFAD-containing fractions were pooled, concentrated on a 
0.5 ml spin filter (MWCO 30 kDa) and analyzed by SDS-PAGE. Absorption spectra 
were recorded on a Lambda 35 UV/Vis spectrometer (Perkin Elmer). The 
fluorescence of FAD was analyzed by the method of Faeder and Siegel (18) using a 
LS55 fluorimeter (Perkin Elmer).  
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RT-PCR analysis, Western blotting, cell fractionation, endoglycosidase H 
(EndoH) digests and immunofluorescence 
Total RNA was isolated (GenElute Total RNA kit, Sigma), the concentration adjusted 
and mRNA reverse transcribed (Enhanced avian reverse transcriptase kit, Sigma). 
PCR reactions with primers specific for ERFAD (for: aagaagccaacaccaacc; rev: 
actcctccaggtactcaaa) and actin (for: ggacttcgagcaagagatgg; rev: agcactgtgttggcgtacag) 
were performed and analyzed on 1% agarose gels. All other methods were performed 
as described previously (31), except for the immunofluorescence on endogenous 
ERFAD where cells were fixed in methanol for 5 min at -20°C. 
 
Transfections and siRNA-mediated knockdown 
Cells were transfected by the calcium phosphate transfection method. For siRNA-
mediated knockdown, four siRNAs against ERFAD and a non-silencing control 
siRNA (QIAGEN) were generated against the target sequences provided in the 
Supplemental Material and Methods.  
 
MG132, zVAD-fmk, and cycloheximide incubations 
MG132 (Sigma, 50 mM stock in DMSO) was used at a final concentration of 5 µM in 
DMEM without FCS. zVAD-fmk (Sigma, 10 mM stock in DMSO) was used at a final 
concentration of 25 µM in DMEM without FCS. Cycloheximide (Sigma, 10 mg/ml 
stock in water) was used at a final concentration of 10 µg/ml in MEMα + 10% FCS. 
 
Metabolic labeling and immunoprecipitations 
Pulse-chase experiments with [35S] Express protein labeling mix (PerkinElmer) and 
immunoprecpitations from cell lysates were performed as described (33), with the 
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exception that before lysis cells were treated with 20 mM NEM in PBS on ice to 
block free cysteines. The following IP lysis buffer was used for native 
immunoprecipitation: 50 mM HEPES/NaOH pH 7.2, 50 mM NaCl, 125 mM K-
acetate, 2 mM MgCl2, 1 mM EDTA, 3 % glycerol, 1% NP-40. Quantification was 
performed on phosphorimager scans using the ImageQuant software (GE Healthcare). 
 
DSP crosslinking 
Cells were washed twice with icecold PBS and then incubated with 1 mM DSP 
(Pierce) in PBS for 20 min. The crosslinking reaction was stopped with 20 mM Tris-
HCl pH 8.0 and 20 mM NEM. 
 
Acknowledgements 
We thank all members of the Ellgaard lab, K. Hendil and J. Winther for helpful 
discussions. We also thank A.M. Lauridsen, A. Kyburz, C. Ashiono and M. Nielsen 
for excellent technical assistance. We thank R. Aebersold, Institute of Molecular 
Systems Biology, ETH Zurich, for help with mass spectrometry. We are grateful to A. 
Helenius, N. E. Ivessa, R. Kopito, M. Peter, L. Hendershot and H. Ploegh for sharing 
reagents, and the Institute of Biochemistry, ETH Zurich for support. Funding was 
obtained from the Novo Nordisk Foundation, the Danish Natural Science Research 
Council and the Novartis Stiftung. J.R. and B.B. are fellows of the Boehringer 
Ingelheim Fonds and C. A.-H. is a fellow of the Swiss National Science Foundation. 
 
References 
1. Anelli, T. & Sitia, R. (2008) Protein quality control in the early secretory 
pathway. EMBO J 27:315-327. 
 17
2. Kincaid, M. M. & Cooper, A. A. (2007) ERADicate ER stress or die trying. 
Antioxid Redox Signal 9:2373-2387. 
3. Nakatsukasa, K. & Brodsky, J. L. (2008) The recognition and 
retrotranslocation of misfolded proteins from the endoplasmic reticulum. 
Traffic 9:861-870. 
4. Kikkert, M., Doolman, R., Dai, M., Avner, R., Hassink, G., van Voorden, S., 
Thanedar, S., Roitelman, J., Chau, V., & Wiertz, E. (2004) Human HRD1 is 
an E3 ubiquitin ligase involved in degradation of proteins from the 
endoplasmic reticulum. J Biol Chem 279:3525-3534. 
5. Mueller, B., Lilley, B. N., & Ploegh, H. L. (2006) SEL1L, the homologue of 
yeast Hrd3p, is involved in protein dislocation from the mammalian ER. J Cell 
Biol 175:261-270. 
6. Lilley, B. N. & Ploegh, H. L. (2005) Multiprotein complexes that link 
dislocation, ubiquitination, and extraction of misfolded proteins from the 
endoplasmic reticulum membrane. Proc Natl Acad Sci U S A 102:14296-
14301. 
7. Mueller, B., Klemm, E. J., Spooner, E., Claessen, J. H., & Ploegh, H. L. 
(2008) SEL1L nucleates a protein complex required for dislocation of 
misfolded glycoproteins. Proc Natl Acad Sci U S A 105:12325-12330. 
8. Christianson, J. C., Shaler, T. A., Tyler, R. E., & Kopito, R. R. (2008) OS-9 
and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin 
ligase complex for ERAD. Nat Cell Biol 10:272-282. 
9. Gauss, R., Jarosch, E., Sommer, T., & Hirsch, C. (2006) A complex of Yos9p 
and the HRD ligase integrates endoplasmic reticulum quality control into the 
degradation machinery. Nat Cell Biol 8:849-854. 
10. Carvalho, P., Goder, V., & Rapoport, T. A. (2006) Distinct ubiquitin-ligase 
complexes define convergent pathways for the degradation of ER proteins. 
Cell 126:361-373. 
11. Denic, V., Quan, E. M., & Weissman, J. S. (2006) A luminal surveillance 
complex that selects misfolded glycoproteins for ER-associated degradation. 
Cell 126:349-359. 
12. Quan, E. M., Kamiya, Y., Kamiya, D., Denic, V., Weibezahn, J., Kato, K., & 
Weissman, J. S. (2008) Defining the glycan destruction signal for endoplasmic 
reticulum-associated degradation. Mol Cell 32:870-877. 
 18
13. Ushioda, R., Hoseki, J., Araki, K., Jansen, G., Thomas, D. Y., & Nagata, K. 
(2008) ERdj5 is required as a disulfide reductase for degradation of misfolded 
proteins in the ER. Science 321:569-572. 
14. Ye, Y., Meyer, H. H., & Rapoport, T. A. (2001) The AAA ATPase Cdc48/p97 
and its partners transport proteins from the ER into the cytosol. Nature 
414:652-656. 
15. Rabinovich, E., Kerem, A., Frohlich, K. U., Diamant, N., & Bar-Nun, S. 
(2002) AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for 
endoplasmic reticulum-associated protein degradation. Mol Cell Biol 22:626-
634. 
16. Suzuki, T., Park, H., Hollingsworth, N. M., Sternglanz, R., & Lennarz, W. J. 
(2000) PNG1, a yeast gene encoding a highly conserved peptide:N-glycanase. 
J Cell Biol 149:1039-1052. 
17. Richly, H., Rape, M., Braun, S., Rumpf, S., Hoege, C., & Jentsch, S. (2005) A 
series of ubiquitin binding factors connects CDC48/p97 to substrate 
multiubiquitylation and proteasomal targeting. Cell 120:73-84. 
18. Faeder, E. J. & Siegel, L. M. (1973) A rapid micromethod for determination of 
FMN and FAD in mixtures. Anal Biochem 53:332-336. 
19. de Virgilio, M., Weninger, H., & Ivessa, N. E. (1998) Ubiquitination is 
required for the retro-translocation of a short-lived luminal endoplasmic 
reticulum glycoprotein to the cytosol for degradation by the proteasome. J Biol 
Chem 273:9734-9743. 
20. Tsao, Y. S., Ivessa, N. E., Adesnik, M., Sabatini, D. D., & Kreibich, G. (1992) 
Carboxy terminally truncated forms of ribophorin I are degraded in pre-Golgi 
compartments by a calcium-dependent process. J Cell Biol 116:57-67. 
21. Cattaneo, M., Otsu, M., Fagioli, C., Martino, S., Lotti, L. V., Sitia, R., & 
Biunno, I. (2008) SEL1L and HRD1 are involved in the degradation of 
unassembled secretory Ig-micro chains. J Cell Physiol 215:794-802. 
22. Okuda-Shimizu, Y. & Hendershot, L. M. (2007) Characterization of an ERAD 
pathway for nonglycosylated BiP substrates, which require Herp. Mol Cell 
28:544-554. 
23. Bernasconi, R., Pertel, T., Luban, J., & Molinari, M. (2008) A dual task for the 
Xbp1-responsive OS-9 variants in the mammalian endoplasmic reticulum: 
 19
inhibiting secretion of misfolded protein conformers and enhancing their 
disposal. J Biol Chem 283:16446-16454. 
24. Hosokawa, N., Wada, I., Nagasawa, K., Moriyama, T., Okawa, K., & Nagata, 
K. (2008) Human XTP3-B Forms an Endoplasmic Reticulum Quality Control 
Scaffold with the HRD1-SEL1L Ubiquitin Ligase Complex and BiP. J Biol 
Chem 283:20914-20924. 
25. Kitzmuller, C., Caprini, A., Moore, S. E., Frenoy, J. P., Schwaiger, E., 
Kellermann, O., Ivessa, N. E., & Ermonval, M. (2003) Processing of N-linked 
glycans during endoplasmic-reticulum-associated degradation of a short-lived 
variant of ribophorin I. Biochem J 376:687-696. 
26. Elkabetz, Y., Shapira, I., Rabinovich, E., & Bar-Nun, S. (2004) Distinct steps 
in dislocation of luminal endoplasmic reticulum-associated degradation 
substrates: roles of endoplamic reticulum-bound p97/Cdc48p and proteasome. 
J Biol Chem 279:3980-3989. 
27. Forster, M. L., Sivick, K., Park, Y. N., Arvan, P., Lencer, W. I., & Tsai, B. 
(2006) Protein disulfide isomerase-like proteins play opposing roles during 
retrotranslocation. J Cell Biol 173:853-859. 
28. Schelhaas, M., Malmstrom, J., Pelkmans, L., Haugstetter, J., Ellgaard, L., 
Grunewald, K., & Helenius, A. (2007) Simian Virus 40 depends on ER protein 
folding and quality control factors for entry into host cells. Cell 131:516-529. 
29. Wahlman, J., DeMartino, G. N., Skach, W. R., Bulleid, N. J., Brodsky, J. L., & 
Johnson, A. E. (2007) Real-time fluorescence detection of ERAD substrate 
retrotranslocation in a mammalian in vitro system. Cell 129:943-955. 
30. Hartmann-Petersen, R., Wallace, M., Hofmann, K., Koch, G., Johnsen, A. H., 
Hendil, K. B., & Gordon, C. (2004) The Ubx2 and Ubx3 cofactors direct 
Cdc48 activity to proteolytic and nonproteolytic ubiquitin-dependent 
processes. Curr Biol 14:824-828. 
31. Haugstetter, J., Blicher, T., & Ellgaard, L. (2005) Identification and 
characterization of a novel thioredoxin-related transmembrane protein of the 
endoplasmic reticulum. J Biol Chem 280:8371-8380. 
32. Perides, G., Plagens, U., & Traub, P. (1986) Protein transfer from fixed, 
stained, and dried polyacrylamide gels and immunoblot with protein A-gold. 
Anal Biochem 152:94-99. 
 20
33. Appenzeller-Herzog, C., Nyfeler, B., Burkhard, P., Santamaria, I., Lopez-Otin, 
C., & Hauri, H. P. (2005) Carbohydrate- and conformation-dependent cargo 
capture for ER-exit. Mol Biol Cell 16:1258-1267. 
 
 
 21
Figure  legends 
Fig. 1: ERFAD is a novel ER flavoprotein. (A) Domain organization of the ERFAD 
protein. The two dinucleotide-binding motifs of the GXGXXG-type for FAD and 
NADPH binding are shown aligned with the corresponding motifs in GR, TR and a 
consensus motif (amino acid residues: h = hydrophobic, o = polar/charged, + = 
positively charged, n = neutral). The sequence positions of the five N-glycosylation 
sites and the six cysteines in ERFAD are depicted. (B) RT-PCR analysis of ERFAD. 
Total RNA was isolated from different human tissue culture cells, reverse transcribed 
and amplified with primers specific for ERFAD and actin. HeLa: cervical epithelial 
carcinoma; Huh7, HepG2: hepatocellular carcinoma; CF-PAC-1: pancreatic adeno 
carcinoma; A375, Meljuso: melanoma; HT1080: fibrosarcoma breast cancer; 
OVCAR3, SKOV3: ovarian epithelial carcinoma; LRB003, LRB010: embryonic stem 
cells (C) Purified recombinant ERFAD-His-FLAG visualized by Coomassie staining. 
(D) Absorption spectra of purified ERFAD-His-FLAG. The two peaks at 370 nm and 
450 nm are indicative of the flavin cofactor. The inset shows the complete spectrum 
including the protein peak at 280 nm. (E) Glycosylation and oxidation state of human 
ERFAD. Lysates from HEK293 cells were treated as indicated, and analyzed by 
Western blotting against endogenous ERFAD. Asterisk, background band; CHO, N-
glycans. (F) Subcellular fractionation of HEK293 cells. After isolation and sodium 
carbonate extraction of crude membranes, followed by ultracentrifugation through a 
sucrose cushion, the distribution of ERFAD, ERp57 (a soluble ER protein) and TMX3 
(an ER membrane protein) was visualized by Western blotting. Asterisk, background 
band. (G) Immunofluorescence microscopy of ERFAD in HEK293 cells. Cells were 
fixed and stained with anti-ERFAD (1F6, red) and anti-Hsp47 (green). A merged 
image is shown in the right panel.  
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Fig. 2: ERFAD interacts with the ERAD components SEL1L and OS-9. (A) 
Immunoprecipitation of ERFAD-HA. Cells stably expressing ERFAD-HA (A11) and 
control cells (FRT) were [35S] pulse-labeled for 16 hours, Triton X-100 lysates 
immunoprecipitated with anti-HA (16B12 and 12CA5), and samples separated by 
reducing SDS-PAGE. The position of a co-immunoprecipitating 90 kDa band is 
indicated by arrowheads. (B) Immunoprecipitation of ERFAD-HA with 16B12, 
undigested (lane 1) and digested (lane 2) with EndoH. The position of the protein 
identified by mass spectrometry – SEL1L – is indicated. CHO, N-glycans. (C) SEL1L 
co-immunoprecipitates with ERFAD-HA. Immunoprecipitations from lysates of A11 
or HEK293 cells were performed with anti-HA, and subsequently analyzed by 
Western blotting as indicated. Asterisk, background band. (D) ERFAD-HA co-
immunoprecipitates with SEL1L. Immunoprecipitations from lysates of A11 cells 
were performed with anti-SEL1L and subsequently analyzed by Western blotting with 
anti-HA, anti-SEL1L (contrast-enhanced blot included to better see the input) and 
anti-p112 as a specificity control. Asterisk, background band. (E) Endogenous 
ERFAD and SEL1L co-immunoprecipitate upon crosslinking with DSP. After 
incubation with DSP, ERFAD was immunoprecipitated from [35S] pulse-labeled 
HEK293 cells. The immunoprecipitate was either analyzed directly (lanes 1 and 4) or 
re-immunoprecipitated with antibodies against SEL1L (lane 2 and 3). For comparison 
an anti-SEL1L immunoprecipitate is loaded in lane 5. Samples were analyzed by 
reducing SDS-PAGE, which resolves the thiol-cleavable crosslink between ERFAD 
and SEL1L. (F) OS-9.1 and 9.2 co-precipitate with ERFAD-HA. 
Immunoprecipitations from A11 or HEK293 cell lysates were performed with anti-
HA, and analyzed by Western blotting with antibodies against OS-9 and the HA tag. 
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Asterisk, background band. (G) Endogenous ERFAD and ERdj5 co-
immunoprecipitate. ERFAD was immunoprecipitated from [35S] pulse-labeled 
HEK293 cells with anti-ERFAD (SG2480). The immunoprecipitate was either 
analyzed directly (lane 1) or re-immunoprecipitated with anti-ERdj5 (lane 2). As a 
control, pre-immune serum was used instead of anti-ERFAD (lanes 3 and 4). In 
another experiment, ERdj5 was immunoprecipitated from pulse-labeled HEK293 cells 
and either analyzed directly (lane 5) or immunoprecipitated with anti-ERFAD (lane 
6). Samples were analyzed by reducing SDS-PAGE. Arrowhead, ERFAD. (H) 
Endogenous ERFAD and ERdj5 co-immunoprecipitate. Immunoprecipitations from 
lysates of HEK293 cells were performed with anti-ERFAD (1F6) or pre-immune 
serum and subsequently analyzed by Western blotting with anti-ERdj5 and anti-
ERFAD. Asterisk, background band. (I) Numerous proteins immunoprecipitate with 
endogenous ERFAD upon DSP crosslinking. Immunoprecipitates of ERFAD after 
treatment with increasing concentrations of DSP were either analyzed reducing or 
non-reducing. Arrows indicate proteins that coprecipitate with ERFAD upon 
crosslinking.  
 
Fig. 3: ERFAD knockdown stabilizes the ERAD model substrate RI332. (A) Decay of 
RI332 upon ERFAD knockdown. HEK293 cells stably expressing RI332 were 
transfected with ERFAD siRNA#1 (#1) and non-silencing control siRNA (c). 72 
hours after transfection cells were pulse labeled for 20 minutes and chased for the 
indicated times. SDS lysates were subjected to immunoprecipitation with anti-
ribophorin. (B) Quantification of three independent RI332 decay experiments (RI332 
signal normalized to full length RI). ***, p<0.005 and *, p<0.5 (C) Ratio of the 
glycosylated ER form of RI332 versus the deglycosylated cytosolic form of RI332 upon 
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ERFAD knockdown. ERFAD-silenced and control HEK-RI332 cells were pulse-
labeled for 20 minutes and chased for 3 hours in the presence of MG132. SDS lysates 
were subjected to immunoprecipitation with anti-ribophorin and half of the eluate was 
PNGaseF treated. The two glycosylation states of RI332 are indicated. (D) 
Quantification of three independent experiments as performed in (C). **, p<0.05 (E) 
Co-immunoprecipitation of ERFAD and RI332. HEK293-RI332 cells were pulse-
labeled for 5 hours in the presence of MG132. Anti-ERFAD immunoprecipitates were 
either analyzed directly (lane 1) or re-immunoprecipitated with anti-ERFAD (lane 2) 
or anti-ribophorin (lane 3). In lanes 4-7 SDS lysates from cells labeled in the presence 
or absence of zVAD-fmk (+MG132) were immunoprecipitated with anti-ribophorin 
with or without subsequent PNGaseF digest to allow the assignment of the three 
different forms of RI332 (RI332+CHO, RI332-CHO and *). The arrowhead indicates the 
minor fraction of deglycosylated RI332 (RI332-CHO) interacting with ERFAD. For a 
contrast-enhanced version see Fig. S6A. 
 
Fig. 4: The knockdown of ERFAD decreases the cellular amount of polyubiquitinated 
proteins. (A) Accumulation of polyubiquitinated proteins upon MG132 treatment. 
HEK293 cells were either left untreated or treated with MG132, lysates were adjusted 
by a BCA assay to the same protein concentration and analyzed by Western blotting 
with anti-ubiquitin. (B) Accumulation of polyubiquitinated proteins upon ERFAD 
knockdown. HEK293 cells were transfected with ERFAD siRNA#1 and non-silencing 
control siRNA (c). Cells were lysed 72 hours after transfection, lysates were adjusted 
to the same concentration and analyzed by Western blotting with anti-ERFAD, anti-
ubiquitin and anti-actin. (C) Quantification of three independent experiments 
performed as described in (B) and plotted as percent of control. 
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